Showing 2931-2940 of 6036 results for "".
- Blanchard Contact Lenses Adds Paragon CRT to Product Portfoliohttps://modernod.com/news/blanchard-contact-lenses-adds-paragon-crt-to-product-portfolio/2478464/Blanchard Contact Lenses announced that it has expanded its product portfolio in the United States to include Paragon CRT and Paragon CRT Dual Axis ortho-k lenses. Paragon CRT and Paragon CRT Dual Axis are reverse geometry corneal lenses manufactured in high-Dk gas permeable lens material
- Bausch + Lomb Introduces SimplifEYE IOL Delivery System for Envista Toric and Monofocal Preloaded IOLshttps://modernod.com/news/bausch-lomb-introduces-simplifeye-iol-delivery-system-for-envista-toric-and-monofocal-preloaded-iols/2478461/Bausch + Lomb announced the introduction of the SimplifEYE IOL delivery system, which is available exclusively for the enVista MX60PL and the enVista toric MX60PT, the first preloaded toric IOL available in the United States. “Surgeons recognize that using a preloaded IOL system can stream
- Nova Eye Medical Establishes “AlphaRET” to Fulfill the Commercial Development of 2RThttps://modernod.com/news/nova-eye-medical-establishes-alpharet-to-fulfill-the-commercial-development-of-2rt/2478458/Nova Eye Medical has announced the reorganization of its 2RT assets via the establishment of AlphaRET Pty Ltd. Establishing AlphaRET, a wholly owned subsidiary of Nova Eye Medical Limited, will enable the company to better concentrate its commercialization efforts for 2RT, and delineate th
- Nicox Selects Development Candidate in a New Class of NO-Mediated IOP Lowering Agentshttps://modernod.com/news/nicox-selects-development-candidate-in-a-new-class-of-no-mediated-iop-lowering-agents/2478452/Nicox SA announced that it has selected a new development candidate, NCX 1728, from its proprietary research program focused on nitric oxide (NO)-mediated IOP lowering agents. An analog of this molecule has demonstrated positive results in ocular hypertensive
- Outpatient Visits Rebound for Most Specialties to Pre-COVID Levelshttps://modernod.com/news/outpatient-visits-rebound-for-most-specialties-to-pre-covid-levels/2478438/After taking a nosedive during the initial wave of the COVID-19 pandemic, then rising and plateauing, weekly outpatient visits in the United States have rebounded and now slightly exceed levels seen in late February, according to new data, Medscape
- Members of Congress Urge Leaders to Act to Protect Patient Access to Surgical Care and Stop Medicare Cutshttps://modernod.com/news/members-of-congress-urge-leaders-to-act-to-protect-patient-access-to-surgical-care-and-stop-medicare-cuts/2478433/A group of 229 Representatives sent a letter
- STRAP Technologies Announces Device to Aid the Visually Impairedhttps://modernod.com/news/strap-technologies-announces-device-to-aid-the-visually-impaired/2478430/STRAP Technologies announced the creation of a hands-free device designed to be worn by the visually impaired to allow for more independence and mobility. STRAP is a wearable, hands-free device with an array of sensors that work by sending real-time information that detect obstacles at the
- Coherent Ships 5,000th OEM ExciStar Devicehttps://modernod.com/news/coherent-ships-5000th-oem-excistar-device/2478427/Coherent recently delivered the 5,000th OEM ExciStar laser for refractive corneal surgery. “The longevity of the laser components and the excellent pulse stability at the ultra-short 193 nm laser wavelength have made the ExciStar family the ideal ablation source for ever faster and m
- CVS, Walgreens Make Deal With Trump Admin to Quickly Distribute COVID-19 Vaccines to Nursing Homeshttps://modernod.com/news/cvs-walgreens-make-deal-with-trump-admin-to-quickly-distribute-covid-19-vaccines-to-nursing-homes/2478429/Retail pharmacy chains CVS Health and Walgreens reached a deal with the Trump administration to quickly provide and administer COVID-19 vaccines directly to nursing homes with no out-of-pocket costs, according to a FierceHealthcare
- Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatmenthttps://modernod.com/news/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment/2478404/Oxular Limited announces it has received both rare paediatric disease and orphan drug designations from the FDA for OXU-003, the company’s proprietary drug in development for the treatment of retinoblastoma. Retinoblastoma is a rare form of eye cancer that usually develops in early childho